Document detail
ID

oai:pubmedcentral.nih.gov:8666...

Topic
Letters to the Editor
Author
Kazama, Itsuro
Langue
en
Editor

BioMed Central

Category

Clinical and Molecular Allergy : CMA

Year

2021

listing date

8/16/2024

Keywords
cells covid-19 prophylactic anaphylaxis
Metrics

Abstract

To fight against coronavirus disease 2019 (COVID-19), the vaccination is currently the most effective approach.

However, in addition to common systemic side effects, the vaccines can cause serious allergic reactions or anaphylaxis.

In anaphylaxis, the exposure to the allergen causes a sudden release of chemical mediators from mast cells, for which adrenaline is the drug of first choice.

In our previous basic studies, in addition to adrenaline, anti-allergic drugs (olopatadine, loratadine, tranilast and ketotifen), antibiotics (clarithromycin), corticosteroids (hydrocortisone and dexamethasone) and certain food constituents (caffeine and catechin) inhibited the process of exocytosis and showed their effectiveness as highly potent mast cell stabilizers.

In these studies, since mast cells were pre-incubated with these drugs or the food constituents before exocytosis was induced, the findings strongly indicated their prophylactic efficacy in stabilizing mast cells.

Considering such pharmacological properties of these commonly prescribed medications or the food constituents, their prophylactic use may potentially be beneficial in preventing anaphylaxis caused by COVID-19 vaccination.

Kazama, Itsuro, 2021, Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis, BioMed Central

Document

Open Open

Share

Source

Articles recommended by ES/IODE AI

Should we consider Systemic Inflammatory Response Index (SIRI) as a new diagnostic marker for rectal cancer?
inflammation rectal surgery overall survival complication significantly diagnostic value cancer rectal 38 siri